Effect of Vibration Anesthesia on Pain, Ecchymosis and Comfort Level in Subcutaneous Heparin Injection

Population and Sample of the Research

The population of the research consisted of the doses administered by subcutaneous heparin injection in the chest diseases clinic of Atatürk University Health Research and Application Center. Among the total data related to the study, 162 patients were evaluated. There were 28 patients who met the study eligibility criteria and 18 who refused to participate in its terms. 116 patients who volunteered to comply with the data collection, total fee criteria and participate will be assigned to the experimental group, 58 patients to the control group, and 58 patients to the control group by randomization. 8 patients from the experimental group left the study because they were discharged early. In the control group, 6 patients were discharged early rather than 2 patients in the study. Training data was completed with 50 patients in both experimental and control classes. To determine whether the sample size was sufficient, post-hoc power analysis was calculated with the G*Power 3.1.9.7 program.

Post hoc power analysis of the study was determined to be over 0.90 with a margin of error of 0.05 for the analysis conducted on the basis of t test in independent groups of the 2nd combination application. Completed with 50 patients in both the experimental and control groups. Post-hoc power analysis was calculated with the G*Power 3.1.9.7 program to determine whether the sample size was sufficient. The power of the study was determined to be above 0.90 with a margin of error of 0.05 for the post hoc power analysis based on the t test in independent groups for the 2nd injection application.

Inclusion Criteria

• Clexane (Enoxaparin Sodium) 0.6 ml SC 1x1 DMAH treatment (0.6 ml heparin was preferred because pain and ecchymosis may be less at a dose of 0.4 ml heparin and the incidence of pain and ecchymosis may increase at a dose of 0.8 ml Clexane.
• No cognitive, physical or mental impairment that prevented them from answering the questions,
• 18 years of age or older,
• No previous known coagulation disorders,
• Platelet value between 150,000 and 300,000/millimeter cubed,
• PTZ value between 10-14 seconds,
• aPTT value between 20-40 seconds,
• INR value between 0.8-1.2,
• No incision, infection, ecchymosis, hematoma, scar tissue in the abdominal region
• No needle phobia
• Not taking pain medication in the last 12 hours
• No abdominal pain
• No other invasive procedures in the abdominal region
• SC heparin not administered by subcutaneous, intramuscular or intradermal injection,
• Patients with no known allergy to heparin,
• Patients with a body mass index above 18.5 were included in the study.